See every side of every news story
Get Started
SubscribeLogin
Hamas
Donald Trump
Ukraine War
Israel-Hamas Conflict
Volodymyr Zelenskyy
Elon Musk
Basketball
Artificial Intelligence
Climate Change
Premier League
Vladimir Putin
US Politics
Published • loading... • Updated

Three-Year Results for EYLEA HD (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals

Summary by ADKhabar
At three years of EYLEA HD treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended dosing regimens, including those of just twice a year: 77%, 58%, 40% and 24% achieved last assigned dosing intervals of ≥3, ≥4, ≥5 and 6 months, respectively At three years, the vast majority of patients […]
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

4 Articles

All
Left
Center
Right
modernretina.commodernretina.com

Regeneron reveals positive results from multiple trials evaluating Eylea HD (aflibercept) injection 8 mg

Results were published from the phase 3 QUASAR trial and the extension study of the phase 3 PULSAR trial.

Read Full Article
Eyewire+Eyewire+

At Angiogenesis, Regeneron Announces New Data for Eylea HD for RVO and Wet AMD

Regeneron announced the first presentation of positive results from the phase 3 QUASAR trial investigating Eylea HD (aflibercept) 8 mg for the treatment of patients with macular edema following retinal vein occlusion (RVO), including those with central, branch and hemiretinal vein occlusions. Regeneron also announced positive 3-year (156-week) results for Eylea HD patients with wet age-related macular degeneration (AMD) from an extension study o…

Read Full Article
pipelinereviewpipelinereview

Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals - Pipelinereview

At three years of EYLEA HD treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended dosing regimens, including those of just twice a year: 77%, 58%, 40% and 24% achieved last assigned dosing intervals of ≥3, ≥4, ≥5 and 6 months, respectively At three years, the vast majority of patients who switched to EYLEA HD from a fixed 2-month dosing regimen with EYLEA® (aflibercept) Injection 2 mg mainta…

Read Full Article
ADKhabarADKhabar

Three-Year Results for EYLEA HD (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals

At three years of EYLEA HD treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended dosing regimens, including those of just twice a year: 77%, 58%, 40% and 24% achieved last assigned dosing intervals of ≥3, ≥4, ≥5 and 6 months, respectively At three years, the vast majority of patients […]

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

ADKhabar broke the news in on Sunday, February 9, 2025.
Sources are mostly out of (0)

Similar News Topics

Tarrytown

Tarrytown

News
For You
Search
BlindspotLocal